CHGCY

Chugai Pharmaceutical Co., Ltd.

OTC Markets OTCPKUSDEQUITY DELAYED

22.19

▲ 0.10 (0.45%)

MARKET · —

Price

Open

21.98

Prev close

22.09

Day high

22.28

Day low

21.98

Volume

31.64K

Market cap

—

P/E (TTM)

—

52W range

20.27 – 34.84

Trailing performance

Price return · vs SPY

Returnvs SPY

+2.97% +4.3%

+0.36% -3.4%

-10.20% -13.3%

-30.89% -42.0%

YTD

-15.53% -27.8%

+1.88% -18.1%

+52.82% -21.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

22.03

+0.72% from price

SMA 20

21.69

+2.30% from price

SMA 50

22.42

-1.04% from price

SMA 100

24.10

-7.93% from price

SMA 200

25.87

-14.23% from price

EMA 12

21.91

+1.27% from price

EMA 26

22.02

+0.78% from price

EMA 50

22.57

-1.67% from price

RSI (14)

51.8

Neutral

MACD (12,26,9)

-0.11

Hist 0.11

ATR (14)

0.72

3.27% of price

Realised vol 30D

31.7%

Annualised

Bollinger upper

22.71

20, 2σ

Bollinger lower

20.67

20, 2σ

50 / 200 cross

Death

22.42 vs 25.87

Trend bias

Below 200

-14.23%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.74

Less volatile than market

Correlation to SPY

0.24

Largely independent

Realised vol 30D

31.7%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-37.8%

Peak to trough

Max drawdown 5Y

-43.5%

Peak to trough

ATR 14

0.72

3.27% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 22.19

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

CHGCY · links out to the publisher

RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors GlobeNewswire · 5d ago Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ... GuruFocus.com · 18d ago Phylo and Chugai partner to advance AI agents in drug discovery PR Newswire · 18d ago Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia PR Newswire · 32d ago Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines Business Wire · 66d ago Immune Thrombocytopenia Market Forecast Signals Steady Growth During the Forecast Period (2026-2036) Backed by Pipeline Advancements | DelveInsight PR Newswire · 86d ago Major Asian Stock Markets Fall Amid Renewed Middle East Tensions MT Newswires · 88d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.